10-Q: BioVie Inc. Reports Second Quarter 2024 Financial Results and Provides Clinical Program Update

BioVie Inc. reports a reduced net loss for the second quarter of 2024 compared to the same period last year, while also providing updates on its clinical programs for Alzheimer's and liver disease.

Summary

• BioVie Inc. reported a net loss of $8.4 million for the three months ended December 31, 2023, compared to a net loss of $15.7 million for the same period in 2022.
• The company's operating expenses decreased to $8.8 million from $11.5 million year-over-year, primarily due to reduced research and development and administrative costs.
• Research and development expenses were $6.5 million for the quarter, down from $7.0 million in the prior year.
• Selling, general, and administrative expenses decreased to $2.3 million from $4.4 million year-over-year.
• For the six months ended December 31, 2023, the net loss was $19.1 million, compared to $26.1 million for the same period in 2022.
• The company had $20.2 million in cash and cash equivalents and $7.5 million in stockholders' equity as of December 31, 2023.
• BioVie is currently finalizing protocol designs for a Phase 3 study of BIV201 for the treatment of ascites due to chronic liver cirrhosis.
• The company is exploring options for its Alzheimer's disease program, including a discussion with the FDA to potentially continue enrolling patients in the current trial or designing a new Phase 3 study.
• The Phase 3 Alzheimer's trial was underpowered due to the exclusion of patients from 15 sites due to protocol violations.
• The company is obligated to pay a low single digit royalty on net sales of BIV201.

Sentiment

Score: 4

Explanation: The document presents mixed signals. While the company has reduced its net loss and is progressing with its clinical programs, the going concern warning, the underpowered Alzheimer's trial, and the shareholder lawsuit raise significant concerns. The need for additional funding and the potential for further dilution also contribute to a negative sentiment.

Positives

• The company's net loss decreased significantly year-over-year for both the three and six month periods ending December 31, 2023.
• Operating expenses were reduced due to the completion of clinical trials and a decrease in stock compensation expense.
• The company has received guidance from the FDA regarding the design and endpoints for definitive clinical testing of BIV201.
• The company has $20.2 million in cash and cash equivalents.
• The company is actively exploring options to advance its Alzheimer's program.

Negatives

• The Phase 3 Alzheimer's trial was underpowered due to significant protocol deviations at 15 study sites.
• The company's future operations are dependent on securing additional financing.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company is in the pre-revenue stage and no revenues are expected in the foreseeable future.
• The company is subject to a shareholder class action lawsuit.

Risks

• The company's reliance on third parties to conduct clinical trials poses a risk to the success of its programs.
• The company's clinical trials may not be successful, and product candidates may not receive regulatory approval.
• The company's ability to access cash or enter into new financing arrangements may be threatened by instability in the financial services industry.
• The company is subject to a shareholder class action lawsuit, which could result in significant expenses and an adverse outcome.
• The company may experience future dilution as a result of future equity offerings.
• The company's majority shareholder has significant control over the company's management.
• The company may issue additional common stock in the future, which would reduce investors' percentage of ownership and may dilute share value.

Future Outlook

The company's future operations are dependent on the success of its ongoing development and commercialization efforts, as well as its ability to secure additional financing. Management expects that future sources of funding may include sales of equity, obtaining loans, or other strategic transactions. The company is exploring options for its Alzheimer's disease program, including a discussion with the FDA to potentially continue enrolling patients in the current trial or designing a new Phase 3 study. The company is currently finalizing protocol designs for the Phase 3 study of BIV201 for the treatment of ascites due to chronic liver cirrhosis.

Management Comments

• Management expects that future sources of funding may include sales of equity, obtaining loans, or other strategic transactions.
• Management continues to pursue the company's strategic plans.
• Management believes the shareholder lawsuit is without merit and intends to defend the case vigorously.

Industry Context

The company is operating in the competitive biopharmaceutical industry, focusing on developing treatments for neurodegenerative diseases and liver disease. The company's focus on inflammation and insulin resistance as drivers of Alzheimer's and Parkinson's disease aligns with emerging scientific consensus. The company's BIV201 program addresses a significant unmet need in the treatment of refractory ascites, a condition with high mortality rates and treatment costs.

Comparison to Industry Standards

• BioVie's approach to targeting neuroinflammation and insulin resistance in neurodegenerative diseases is similar to other companies exploring novel mechanisms of action in this space, such as AC Immune SA and Cassava Sciences, Inc., though the specific molecules and pathways differ.
• The company's BIV201 program for refractory ascites is unique, as there are currently no FDA-approved drugs for this condition, setting it apart from companies focused on more established treatments.
• The company's financial results, particularly the net losses and cash burn, are typical for a clinical-stage biopharmaceutical company, but the going concern warning is a concern.
• The company's reliance on third-party CROs for clinical trials is standard practice in the industry, but the protocol violations at 15 sites in the Alzheimer's trial highlight the risks associated with this model.
• The company's royalty obligations on BIV201 are common in the industry, particularly for acquired assets.

Legal Proceedings

• A shareholder class action complaint was filed against the company on January 19, 2024, alleging material misrepresentations and/or omissions of material fact relating to the company's business, operations, compliance, and prospects, including information related to the study and trial of NE3107.

Related Party Transactions

• On July 15, 2022, the Company entered into a securities purchase agreement with Acuitas Group Holdings, LLC (Acuitas), the Company’s majority stockholder, pursuant to which Acuitas agreed to purchase from the Company, in a private placement, an aggregate of 3,636,364 shares of the Company’s Common Stock, at a price of $1.65 per share and a warrant to purchase 7,272,728 shares of Common Stock at an exercise price of $1.82.

Stakeholder Impact

• Shareholders are impacted by the company's financial performance, the potential for dilution, and the shareholder class action lawsuit.
• Employees are impacted by the company's financial stability and the potential for future layoffs or restructuring.
• Customers (potential patients) are impacted by the progress of the company's clinical programs and the potential availability of new treatments.
• Suppliers and creditors are impacted by the company's ability to meet its financial obligations.
• The company's clinical trial sites are impacted by the company's compliance with regulatory requirements and the potential for future collaborations.

Next Steps

• The company is finalizing protocol designs for a Phase 3 study of BIV201 for the treatment of ascites due to chronic liver cirrhosis.
• The company is exploring options for its Alzheimer's disease program, including a discussion with the FDA to potentially continue enrolling patients in the current trial or designing a new Phase 3 study.
• The company will continue to seek additional financing to fund its operations.

Key Dates

Keywords

Clinical-stage, Pharmaceutical, NE3107, BIV201, Alzheimer's Disease, Parkinson's Disease, Liver Disease, Ascites, Clinical Trials, FDA, Financial Results